Clareo Health | Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age: ≥ 40 years;
2. Diagnosis of COPD and met the following criteria:
1. Relatively stable, moderate to severe airway obstruction,
2. Baseline 30% ≤ FEV1 ≤ 65% of predicted normal value, predicted normal values are based on the guidelines for standardized lung function testing of the European Community for Coal and Steel (ECCS) ,
3. Smoking history ≥ 10 pack-years (p.y.). A p.y. is defined as the equivalent of smoking one pack of cigarettes per day for one year;
4. Male of female;
5. Ability to be trained in the proper use of Respimat and Handihaler;
6. Ability to be trained in the performance of technically satisfactory pulmonary function tests;
7. Ability to provide written informed consent
8. Patient affiliated to the Social Security System
You may not be if
1. History of asthma, allergic rhinitis or atopy or who have a blood eosinophil count above 600/mm³
2. Changes in the therapeutic (pulmonary) plan within the last six weeks prior to the Screening Visit;
3. Treatment by cromolyn/nedocromil sodium;
4. Treatment by antihistamines (H1 receptor antagonists);
5. A lower respiratory tract infection or any exacerbation in the past six weeks prior to the Screening Visit;
6. Regular use of daytime oxygen therapy;
7. Treatment by oral corticosteroid medication if initiated or modified within the last six weeks or if daily dose \> 10 mg prednisone equivalent;
8. History of life threatening pulmonary obstruction, cystic fibrosis or bronchiectasis
9. Patients who have undergone thoracotomy with pulmonary resection;
10. History of clinically significant cardiovascular, renal neurologic, liver or endocrine dysfunction. A clinically significant disease was defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
11. Patients with a recent (≤ one year) history of myocardial infarction, of heart failure or patients with any cardiac arrhythmia requiring drug therapy;
12. Tuberculosis with indication for treatment;
13. History of cancer within the last five years. Patients with treated basal cell carcinoma were allowed:
14. Current psychiatric disorders;
15. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction;
16. Patients with any history of glaucoma or increased intra-ocular pressure;
17. Patients with clinically significant abnormal baseline haematology or blood chemistry, if the abnormality defines a disease listed as an exclusion criterion;
18. Patients with
1. glutamyl-oxalo-acetic transaminase/glutamyl-pyruvic transaminase (SGOT/SGPT): \> 200% of the upper limit of the normal range (ULN, )
2. bilirubin: \> 150% of the ULN,
3. creatinine: \> 125% of the ULN;
19. Intolerance to aerosolised anticholinergic containing products, and/or hypersensitivity to benzalkonium chloride, to lactose or any other components of the inhalation capsule delivery system;
20. Beta-blocker medication;
21. Concomitant or recent (within the last month) use of investigational drugs;
22. History of drug abuse and/or alcoholism;
23. Pregnant or nursing women and women of childbearing potential not using a medically approved means of contraception ( urinary pregnancy test at screening);
24. Previous participation in this study (i.e. having been allocated a randomised treatment number);
25. Patients deprived of their freedom by a judicial or administrative decision;
